These include an initial phase-1 trial at the Baylor College of Medicine, Houston, TX, USA and a phase-1b study in Brazil to assess the vaccine’s immunogenicity and safety in a group of healthy adults who may have been previously exposed to schistosomiasis; further trialing of Sm-TSP-2 are planned for Uganda (https://clinicaltrials.gov/ct2/show/{“type”:”clinicaltrial”,”attrs”:{“text”:”NCT03910972”,”term_id”:”NCT03910972”}}NCT03910972) (accessed on 20 July 2021) [29]. This evidence concerns the gene THBS2 and schistosomiasis.